Photo by jontyson from unsplash
Anti‐CD47 (Hu5F9‐G4) is a human monoclonal immunoglobulin G (IgG)4 antibody that is in clinical trials to treat hematologic or solid malignancies. CD47, a glycoprotein expressed on all cells, binds to… Click to show full abstract
Anti‐CD47 (Hu5F9‐G4) is a human monoclonal immunoglobulin G (IgG)4 antibody that is in clinical trials to treat hematologic or solid malignancies. CD47, a glycoprotein expressed on all cells, binds to signal‐regulatory protein α on macrophages and regulates phagocytosis. Blocking CD47 is thought to enhance phagocytosis and promote antitumor responses. Here, we evaluate drug interference in pretransfusion testing, determine mitigation strategies, and compare interference with anti‐CD38 (Daratumumab).
Keywords:
anti cd47;
monoclonal anti;
interference;
cd47 interference
Journal Title: Transfusion
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Transfusion
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!